Provided By GlobeNewswire
Last update: Nov 5, 2024
Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors
Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials
Read more at globenewswire.comNASDAQ:TSBX (7/28/2025, 4:30:01 PM)
0.3525
-0.01 (-2.08%)
Find more stocks in the Stock Screener